<DOC>
	<DOCNO>NCT00959764</DOCNO>
	<brief_summary>The purpose study compare effectiveness tolerability two medication , calcitonin nasal spray tablet contain calcitonin , postmenopausal woman osteoporosis . Osteoporosis term use describe large group disease , characterize loss bone density , make bone weak . Osteoporosis often occur postmenopausal woman . Calcitonin hormone find human body . Together substance , regulate concentration calcium blood inhibits natural resorption bone . Both medication study contain salmon calcitonin ( sCT ) , form calcitonin active human calcitonin use medicine . The calcitonin Nasal Spray use study register available doctor United States treatment osteoporosis . The medication test study oral tablet form salmon calcitonin .</brief_summary>
	<brief_title>A Study Comparing Oral Calcitonin Nasal Spray Calcitonin Postmenopausal Osteoporotic Women</brief_title>
	<detailed_description>This randomize , double-blind , double-dummy , multiple dose , placebo-controlled , parallel group , 48- week , Phase III study . Women age 45 postmenopausal diagnosis osteoporosis eligible study randomly allocate one three treatment group ; placebo tablet , oral rsCT tablet calcitonin nasal spray . Each patient give treatment kit , contain study medication assign placebo treatment assign , placebo nasal oral preparation , well required dietary supplement ( calcium vitamin D tablet ) . The study medication supplement self-administered home . It anticipate approximately 545 patient would participate study . EFFICACY : Bone Mineral Density ( BMD ) record Screening , Week 24 , Week 48 . CTx-1 N-telopeptide collagen 1 ( NTx-1 ) , biochemical marker bone resorption total Procollagen type 1 N-terminal propeptide ( P1NP ) , marker bone formation , assess Week 0 , Week 24 , Week 48 . SAFETY : Adverse event assess clinic Weeks 0 , 12 , 24 , 36 48 , interim phone call Weeks 4 , 8 , 16 , 20 , 28 , 32 , 40 , 44 , 52 . At Screening , Week 12 , Week 48 , physical examination , include nasal exam , perform specimen safety laboratory analysis ( clinical chemistry , hematology , urinalysis ) collect . Sera immunogenicity evaluation collect Baseline , Week 12 , Week 48 . EFFICACY : The primary comparison interest percent change baseline 48 week axial lumbar spine ( L1 L4 ) correct BMD compare rsCT oral tablet group calcitonin nasal spray group . The model include factor covariate ( baseline BMD ) , treatment group , center . The hypothesis test performed examine non-inferiority oral tablet group nasal spray group respect percent change axial lumbar L1-L4 spine correct BMD . Specifically , null hypothesis test : [ Mean ( oral ) - Mean ( placebo ) ] - 0.5 x [ Mean ( nasal ) - Mean ( placebo ) ] &lt; 0 The alternative hypothesis expression &gt; 0 , imply oral tablet group non-inferior nasal spray group . The primary analysis interest employ modify intent-to-treat population . SAFETY : Adverse event summarize descriptively . Mean vital sign clinical laboratory test result treatment group compare use one-way analysis variance . Additionally , shift table prepare laboratory variable .</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis , Postmenopausal</mesh_term>
	<mesh_term>Salmon calcitonin</mesh_term>
	<mesh_term>Calcitonin</mesh_term>
	<mesh_term>Calcitonin Gene-Related Peptide</mesh_term>
	<criteria>Female age 45 . Must undergone onset spontaneous surgical menopause . Spontaneous menopause define 12 month spontaneous amenorrhea 6 month spontaneous amenorrhea serum Follicle Stimulating Hormone ( FSH ) level &gt; 40 milliinternational unit ( mIU ) /milliliter ( mL ) 6 week postsurgical bilateral oophorectomy without hysterectomy . Diagnosis osteoporosis basis axial lumbar spine , femoral neck total hip BMD mean premenopausal woman magnitude least 2.5 SD 2.0 SD , document history vertebral fragility fracture . Must least three contiguous lumbar vertebra ( L1L4 ) evaluable DXA BMD , without fracture significant degenerative disease , determine BioImaging Technologies , Inc. No clinically significant abnormal finding medical history , physical exam nasal exam . No clinically significant abnormal laboratory value screen assessment . History severe allergic disease . History metabolic bone disease , include osteogenesis imperfecta , osteomalacia , Paget 's disease . Vitamin D insufficiency define 25 hydroxyvitamin D level &lt; 20 ng/mL . Use intravenous bisphosphonate past 24 month , &gt; 2 dos intravenous bisphosphonate ever . Use oral bisphosphonate randomization , include investigational bisphosphonates , unless : 1 ) less 6 month treatment 6 month , 2 ) 6 12 month treatment 2 year , 3 ) More 12 month treatment 5 year Use denosumab , fluoride , strontium , ever . Use parathyroid hormone analog bone metabolic agent within 1 year precede randomization . Any condition disease may interfere ability DXA scan evaluate DXA scan , example , severe osteoarthritis spine , spinal fusion , pedicle screw , history vertebroplasty , degenerative disease result insufficient number evaluable lumbar vertebra , 1 lumbar vertebral fracture L1 L4 . ( More 4 vertebral fracture T4 L4 ; Bilateral hip replacement ) Use anabolic steroid androgen within 6 month precede randomization . Use Vitamin D metabolites analog , ( e.g. , calcitriol ) within 3 month precede randomization ) . Note : Vitamin D supplementation exclusionary . Use estrogen estrogenrelated drug , example , tamoxifen , tibolone , raloxifene within 3 month precede randomization . Use coumadin within 4 week precede randomization heparin within 1 week precede randomization . Chronic systemic treatment glucocorticoid , hormone replacement therapy , calcitonin medication within previous three month , opinion Investigator , would interfere study . Clinically relevant abnormal history , physical finding laboratory value prestudy screen assessment could interfere objective study safety patient . Presence acute chronic illness history chronic illness , judgment Investigator , make participation study medically inappropriate . Uncontrolled hypertension , significant gastrointestinal abnormality , uncontrolled diabetes mellitus , significant coronary heart disease , psychotic mental illness , chronic allergic rhinitis , asthma , uncorrected endocrine dysfunction , significantly impaired hepatic , respiratory renal function . History drug alcohol abuse , intake 30 unit alcohol weekly .</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
</DOC>